A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

The developer of products for biopharmaceutical companies and research and academic institutions files for bankruptcy.

Dr. Andrew M. Evens breaks down what it means to be an adolescent or young adult with lymphoma and how treatment differs from ...

A global study suggests that using small molecule inhibitors followed by epigenetic modifiers may significantly improve ...

Apr. 29, 2025 — A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete ...

Roughly 200,000 people are diagnosed with a blood cancer on a yearly basis. Blood cancer will claim the lives of 55,000 Americans every year.

DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology ...

In addition to the receptor used to locate tumor cells, this treatment adds an element that further enhances the immune ...